MELD-Plus (original) (raw)
MELD-Plus is a risk score to assess severity of chronic liver disease that was resulted from a collaboration between Massachusetts General Hospital and IBM. The score includes nine variables as effective predictors for 90-day mortality after a discharge from a cirrhosis-related admission. The variables include all Model for End-Stage Liver Disease (MELD)'s components, as well as sodium, albumin, total cholesterol, white blood cell count, age, and length of stay.
| Property | Value |
|---|---|
| dbo:abstract | MELD-Plus is a risk score to assess severity of chronic liver disease that was resulted from a collaboration between Massachusetts General Hospital and IBM. The score includes nine variables as effective predictors for 90-day mortality after a discharge from a cirrhosis-related admission. The variables include all Model for End-Stage Liver Disease (MELD)'s components, as well as sodium, albumin, total cholesterol, white blood cell count, age, and length of stay. Because total cholesterol and hospital length of stay are typically not uniform factors across different hospitals and may vary in different countries, an additional model that included only seven of the nine variables was evaluated. This yielded a performance close to the one of using all nine variables and resulted in the following associations with increased mortality: INR, creatinine, total bilirubin, sodium, WBC, albumin, and age. The development of MELD-Plus was based on using unbiased approach toward discovery of biomarkers. In this approach, a feature selection machine learning algorithm observes a large collection of health records and identifies a small set of variables that could serve as the most efficient predictors for a given medical outcome. An example for a notable feature selection method is lasso (least absolute shrinkage and selection operator). (en) |
| dbo:thumbnail | wiki-commons:Special:FilePath/Uri_Kartoun_princeton_nov_2018.jpg?width=300 |
| dbo:wikiPageID | 55667828 (xsd:integer) |
| dbo:wikiPageLength | 14706 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1107899810 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:United_Network_for_Organ_Sharing dbr:Massachusetts_General_Hospital dbr:GitHub dbr:Liver_transplantation dbr:Machine_learning dbr:Feature_selection dbc:Hepatology dbr:Acute_kidney_injury dbr:Chronic_liver_disease dbr:Hepatic_encephalopathy dbc:Medical_scoring_system dbr:Transplantation_(journal) dbr:IBM dbr:New_England_Journal_of_Medicine dbr:Model_for_End-Stage_Liver_Disease dbr:European_Journal_of_Gastroenterology_&_Hepatology dbr:Surgery,_Gastroenterology_and_Oncology |
| dbp:caption | Uri Kartoun presenting MELD-Plus at Princeton University, November 2018 (en) |
| dbp:name | MELD-Plus (en) |
| dbp:purpose | Assess severity of chronic liver disease (en) |
| dbp:wikiPageUsesTemplate | dbt:Infobox_diagnostic dbt:Reflist dbt:Short_description |
| dcterms:subject | dbc:Hepatology dbc:Medical_scoring_system |
| rdfs:comment | MELD-Plus is a risk score to assess severity of chronic liver disease that was resulted from a collaboration between Massachusetts General Hospital and IBM. The score includes nine variables as effective predictors for 90-day mortality after a discharge from a cirrhosis-related admission. The variables include all Model for End-Stage Liver Disease (MELD)'s components, as well as sodium, albumin, total cholesterol, white blood cell count, age, and length of stay. (en) |
| rdfs:label | MELD-Plus (en) |
| owl:sameAs | wikidata:MELD-Plus https://global.dbpedia.org/id/4Xcnw |
| prov:wasDerivedFrom | wikipedia-en:MELD-Plus?oldid=1107899810&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Uri_Kartoun_princeton_nov_2018.jpg |
| foaf:isPrimaryTopicOf | wikipedia-en:MELD-Plus |
| is dbo:wikiPageWikiLink of | dbr:Pediatric_end-stage_liver_disease dbr:United_Kingdom_Model_for_End-Stage_Liver_Disease dbr:Child–Pugh_score dbr:Cirrhosis dbr:Chronic_liver_disease dbr:Model_for_End-Stage_Liver_Disease dbr:IBM_Research |
| is foaf:primaryTopic of | wikipedia-en:MELD-Plus |
